Docket No.: 14167-00002-US

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Sven Klussmann et al.

Application No.: 10/578938

Confirmation No.: Not Yet Assigned

Filed: May 9, 2006

Art Unit: Not Yet Assigned

For:

NUCLEIC ACIDS SPECIFICALLY

BINDING BIOACTIVE GHRELIN

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Application No.: 10/578938 Docket No.: 14167-00002-US

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 14167-00002-US. A duplicate copy of this paper is enclosed.

Dated: July 20, 3006

Respectfully submitted,

Liza D. Hohenschutz

Registration No.: 33,712

CONNOLLY BOVE LODGE & HUTZ LLP

1007 North Orange Street

P.O. Box 2207

Wilmington, Delaware 19899

(302) 658-9141

(302) 658-5614 (Fax)

Attorney for Applicant

14167-00002-US

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO 10/578938 Application Number INFORMATION DISCLOSURE May 9, 2006 Filing Date STATEMENT BY APPLICANT Sven Klussmann First Named Inventor 1637 Art Unit Not-Yet-Assigned (Use as many sheets as necessary) Not Yet Assigned S. Pande Examiner Name

Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear	

Sheet

1

of

1

FOREIGN PATENT DOCUMENTS						
Examiner	Cite No.¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				T ⁶
/S.P	BA	WO 2004/013274 A21	02-12-2004	Noxxon Pharma AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), and/or country where published.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
/S.P./	CA	S. J. Wood, "DNA-DNA Hybridization in Real Time Using BlAcore", Microchemical Journal, 47, pages 330-337, 1993		
/S.P	СВ	S. Helmling et al., "Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer", PNAS, vol. 101, no. 36, pages 13174-13179, September 7, 2004		
/S.P.	cc	M. Raghavan et al., "BIAcore: a microchip -based system for anlyzing the formation of macromolecular complexes", Structure, vol. 3, pages 331-333, April 15, 1995		
/S.P.,	CD	S. Leva et al., "GnRH bining RNA and DNA Spiegelmers: A Novel Approach toward GnRH Antagonism", Chemistry & Biology, vol. 9, pages 351-359, March 2002		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Suchira Pande/	Date	06/17/2008
Signature		Considered	

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.